

October 18, 2022

**BSE Limited**  
P.J. Towers,  
Dalal Street,  
Mumbai-400001  
Scrip Code: 530239

**National Stock Exchange of India Limited**  
“Exchange Plaza”,  
Bandra-Kurla Complex, Bandra (East),  
Mumbai-400051.  
Scrip Symbol: SUVEN

Dear Sir/Madam,

**Sub: Outcome of the meeting of the Rights Issue Committee of Board of Directors of Suven Life Sciences Limited (“Company”) held today i.e. Tuesday, October 18, 2022.**

**Ref.: Disclosure & Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“SEBI Listing Regulations”)**

In furtherance to our intimation dated October 12, 2022 informing approval of the terms and conditions of the Rights Issue, we wish to inform that Rights Issue Committee of the Board of Directors of the Company, at their meeting held today i.e. Tuesday, October 18, 2022, **inter-alia considered and approved the following:**

- a) **Issue period:**
1. Issue Opening Date: Monday, October 31, 2022
  2. Issue Closing Date: Thursday, November 10, 2022
- b) the **Letter of Offer (LOF)** to be filed with Securities and Exchange Board of India, BSE Limited and National Stock Exchange of India Limited.

The meeting of the committee commenced at 05:00 p.m. and concluded at 05:55 p.m.

This is for your information as also for the information of your members and the public at large.

Thanking you,

Yours faithfully,  
**For Suven Life Sciences Limited**

**Shrenik Soni**  
**Company Secretary**

## **Suven Life Sciences Limited**

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com